Proud of Your Giant Tax Refund? Congrats, You Just Gave the Government an Interest-Free Loan
It might feel like a sudden windfall, but it's not. It's essentially an interest-free loan you gave the U.S. government through payroll tax deductions — you just didn't collect it until many months later, after you filed your tax return and Uncle Sam finally paid you back.
Explore More:
Read Next:
GOBankingRates breaks down how this works and how you can adjust your finances to keep more of your money.
Refunds are 'simply the government returning your own money — money that you overpaid, expecting no interest in return,' according to a blog from GYL, a California-based provider of accounting, audit, business advisory and tax services.
Tax refunds might serve a useful purpose for some people, such as those who have a hard time saving money on their own. In this case, exchanging a bigger-than-necessary payroll tax deduction for a one-time refund might make sense.
But for everyone else, that exchange amounts to lost financial opportunity, experts say.
'The IRS uses your overpaid taxes throughout the fiscal year, only to return them post-tax filing, without any financial benefit to you,' GYL noted. 'Commonly this interest-free loan to the government is inadvertently costing you money that could be generating interest or invested for potential gains.'
Check Out:
Pisenti & Brinker, another California-based financial advisory and consulting firm, offered a similar take in one of its blogs, suggesting that 'smart taxpayers understand that refunds actually cost them money.'
'Kept in your hands, those dollars could have been productive,' Pisenti & Brinker added. 'For example, you could have invested the money or used it to pay off your debt during the year. If the money had been added to a 401(k) plan, tax would have been deferred on both the investment and its earnings. Even better, your employer might have matched all or part of your investment, adding to your retirement savings.'
If you'd rather keep more money for yourself each paycheck rather than loan it to the government, the best solution is to set up your payroll withholding so that you more or less break even during the tax year. This means that when you file your tax return, you won't owe a lot in taxes or qualify for a big refund. Ideally, the dollar amount on either side of the equation will be minimal.
You can figure out the best amount to withhold by consulting with a tax advisor, financial professional or your employer's HR department. You can also use the IRS's tax withholding estimator. The right amount depends on a few different factors, including your household income, number of dependents and filing status.
More From GOBankingRates
5 Luxury Cars That Will Have Massive Price Drops in Spring 2025
4 Things You Should Do if You Want To Retire Early
5 Cities You Need To Consider If You're Retiring in 2025
10 Cars That Outlast the Average Vehicle
This article originally appeared on GOBankingRates.com: Proud of Your Giant Tax Refund? Congrats, You Just Gave the Government an Interest-Free Loan

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
2 hours ago
- Associated Press
PAL Investors Have Opportunity to Join Proficient Auto Logistics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--Jul 13, 2025-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Proficient Auto Logistics, Inc. ('Proficient Auto' or 'the Company') (NASDAQ: PAL ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Proficient Auto announced its Q1 financial results on May 7, 2025. The Company suffered a decline in year-over-year total operating revenue as well as reporting a net operating loss. Based on this news, shares of Proficient Auto fell by more than 4.9% on the next day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at [email protected]. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. View source version on CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335 [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: The Schall Law Firm Copyright Business Wire 2025. PUB: 07/13/2025 03:41 PM/DISC: 07/13/2025 03:41 PM


Associated Press
2 hours ago
- Associated Press
LASE Investors Have Opportunity to Join Laser Photonics Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--Jul 13, 2025-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Laser Photonics Corporation ('Laser Photonics' or 'the Company') (NASDAQ: LASE ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Laser Photonics disclosed in a May 29, 2025, SEC filing that it had 'received a notice from Nasdaq Listing Qualifications department of the Nasdaq Stock Market LLC ('Nasdaq') stating that since it had not received the Company's Form 10-Q for the period ended March 31, 2025, and because the Company remains delinquent in filing its Form 10-K for the period ended December 31, 2024 (the 'Initial Delinquent Filing'), the Company does not comply with Nasdaq's Listing Rules for continued listing.' The filing continued, 'the Company has until June 16, 2025, to submit a plan to regain compliance with respect to these delinquent reports.' Based on this news, shares of Laser Photonics fell by more than 6.5% on the next day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at [email protected]. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. View source version on CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335 [email protected] KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: The Schall Law Firm Copyright Business Wire 2025. PUB: 07/13/2025 03:36 PM/DISC: 07/13/2025 03:36 PM

Associated Press
2 hours ago
- Associated Press
DEA Crushes Illegal Marijuana - But Still Blocks MMJ's Legal Cannabis Drug for Huntington's
While busting cartels, DEA continues war on science and suffering patients. Duane Boise, CEO of MMJ International Holdings, expressed frustration over the contrasting approaches of federal agencies, stating, 'While the FDA is facilitating medical innovation, the DEA's hindrance not only blocks scientific progress but also contradicts directives aimed at revitalizing domestic manufacturing.' This situation starkly contrasts with the 'Buy American' initiative endorsed by President Trump, which was intended to strengthen U.S. drug production capabilities and reduce dependence on foreign manufacturers. WASHINGTON, DC / ACCESS Newswire / July 13, 2025 / In a historic move, the Drug Enforcement Administration (DEA), alongside California officials, seized over $123 million in illegal cannabis in California's Central Valley. Touted as the largest cannabis eradication operation in state history, this multi-agency sweep destroyed 105,700 illegal plants and over 22,000 pounds of processed product-dealing a powerful blow to criminal diversion networks. But while the DEA proudly parades its enforcement success, it continues to obstruct a very different kind of cannabis operation-one backed by the FDA, supported by Congress, and desperately needed by patients. Why is the DEA targeting drug cartels, while simultaneously blocking science and medical progress? The DEA Operation: A Win Against Illicit Growers During the week of May 5, a coordinated task force involving the DEA, California National Guard, state and local law enforcement, and the Department of Fish and Wildlife executed dozens of warrants across Kern, Tulare, and Kings counties. Nine firearms were seized and multiple individuals arrested. 'This operation demonstrates the power of collaboration to dismantle criminal enterprises,' said California officials. But one form of cannabis remains untouched: federally compliant, FDA authorized medical cannabis research. DEA's Double Standard: Criminal Cartels Get Raided-Pharmaceutical Innovation Gets Sabotaged Despite this public victory, the DEA's track record tells a darker story: It targets illegal grows tainted with pesticides and mold But blocks companies like MMJ BioPharma Cultivation, which holds: Yet the agency continues to deny MMJ a bulk manufacturing license after nearly seven years of delay-citing retroactive 'Catch-22" policies and hiding behind a broken administrative law system. Obstructing Science While Crime Thrives While criminal operations flood state-legal markets with contaminated cannabis, the DEA has stood by, doing little to protect public health-until now. But even this long-overdue enforcement does not excuse the agency's refusal to act on federally authorized medical research. 'This isn't just negligence-it's sabotage,' said Duane Boise, CEO of MMJ BioPharma. 'We followed every federal rule, obtained FDA approvals, and proved our security protocols. The DEA's refusal to grant a license has delayed critical treatment for patients suffering from Huntington's Disease and Multiple Sclerosis.' A National Embarrassment MMJ BioPharma's situation has become a symbol of DEA dysfunction: Meanwhile, illicit grows flourish-and so does patient suffering. The Path Forward: Reform, Not Excuses With President Trump threatening 200% tariffs to bring pharmaceutical manufacturing back to U.S. soil, the DEA's outdated war on cannabis could derail America's pharmaceutical future before it starts. MMJ BioPharma calls for the following immediate actions: Remove DEA roadblocks to FDA-approved medical cannabis research Transfer cannabis pharmaceutical oversight to the FDA or NIH Investigate the DEA Diversion Control Division for systemic obstruction A Final Word: 'The DEA cannot be allowed to fight cartels with one hand and choke science with the other,' said Boise. 'Lives are on the line. We need enforcement-but we also need research progress.' MMJ is represented by attorney Megan Sheehan. CONTACT: Madison Hisey [email protected] 203-231-85832 SOURCE: MMJ International Holdings press release